Duke Energy Foundation, City of New Port Richey Team Up for Summer Swim Safety
NEW PORT RICHEY, Fla., May 29, 2025 /3BL/ - In recognition of the May 15 designation as International Water Safety Day, Duke Energy Foundation announces a grant to the City of New Port Richey for swim lessons and summer camp scholarships.
'Safety is central to how we operate at Duke Energy. Providing water safety education through swim lessons is a fun but important way to keep children in our community safe this summer,' said Melissa Seixas, Duke Energy Florida state president. 'We thank the City of New Port Richey for providing programming to families throughout the year and are happy to make these programs available to more children this summer.'
The City of New Port Richey is offering summer day camp to residents June 2-Aug. 8 this summer. Registration is available by calling the Recreation and Aquatic Center at 727.841.4560 or visiting www.citynpr.org. Limited spots are still available.
'We're incredibly grateful to Duke Energy Foundation for supporting our efforts to keep kids safe and active all summer long,' said Kevin Trapp, assistant parks and recreation director. 'This funding helps remove barriers for families and ensures more children can enjoy swim lessons and camp experiences that build confidence and lifelong safety skills.'
Below are the top water safety tips from the American Red Cross, as an important reminder to all of us, on how to keep yourself, your family and friends safe in and around the water every day.
For more information on water safety, please visit American Red Cross' water safety resources here.
Duke Energy Foundation
Duke Energy Foundation provides more than $30 million annually in philanthropic support to meet the needs of communities where Duke Energy customers live and work. The Foundation is funded by Duke Energy shareholders.
Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America's largest energy holding companies. The company's electric utilities serve 8.6 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 55,100 megawatts of energy capacity. Its natural gas utilities serve 1.7 million customers in North Carolina, South Carolina, Tennessee, Ohio and Kentucky.
About Duke Energy FloridaDuke Energy Florida, a subsidiary of Duke Energy, owns 12,500 megawatts of energy capacity, supplying electricity to 2 million residential, commercial and industrial customers across a 13,000-square-mile service area in Florida.
About City of New Port Richey:
With a strong local government, an attractive historical downtown, and a unique riverfront landscape, New Port Richey is one of Florida's best walkable, waterfront, historic hometowns. For more information, visit www.cityofnewportrichey.org.
Media contact: Laitin SterlingMedia line: 800.559.3853
View original content here.
Visit 3BL Media to see more multimedia and stories from Duke Energy Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th Annual Global Healthcare Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, June 10th at 2:00 p.m. Eastern Time. Citizens Medical Devices and Healthcare Services Forum: Ben Berry, Chief Financial Officer, will participate in investor meetings on Tuesday, June 17th. A link to the live audio webcasts, if available, as well as a replay of these events, will be available on the Company's website under the Investors tab at Events and Presentations. ABOUT ENOVIS Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company's extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company's shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit Contact: Kyle RoseVice President, Investor RelationsEnovis Corporationinvestorrelations@
Yahoo
5 hours ago
- Yahoo
Should You Invest $1,000 in Eli Lilly today?
Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight loss market could represent a multibillion-dollar opportunity well into the next decade. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. The pharma giant's presence across several treatment areas has helped it grow earnings over time. But, in recent years, one particular product portfolio has stood out and driven double-digit revenue growth: drugs to help people lose weight. Right now, Lilly sells tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight loss, though doctors have prescribed either one for patients hoping to shed pounds. Mounjaro and Zepbound each have become blockbusters, bringing in billion-dollar revenue annually. Lilly dominates the weight loss market along with rival Novo Nordisk, but a recent move by Lilly could help it push farther ahead in the coming years. Considering this, should you invest $1,000 in Lilly stock today? Let's find out. So, first, let's talk about Lilly's path so far in this market and what might lie ahead. Lilly's weight loss drugs are part of a class known as dual GIP and GLP-1 receptor agonists. They act on hormonal pathways involved in the digestion process and help control blood sugar levels and appetite. Novo Nordisk's rival drug, semaglutide -- sold as Ozempic for type 2 diabetes and Wegovy for weight loss -- targets only GLP-1 but works in a similar way. Novo Nordisk was first to market with its product, winning approval for Ozempic in 2017, and this offered it time to build a market-leading position. But demand has been so high for such weight loss drugs that Lilly quickly gained share soon after entering the market with Mounjaro in 2022 and then with Zepbound in 2023. In fact, demand has been so strong that these drugs held spots on the U.S. Food and Drug Administration's drug shortage list for quite some time, only exiting the list in recent months. A better supply situation for weight loss drugs isn't due to a drop in demand but instead to increases in manufacturing capacity by both companies. So solid demand for these products still exists -- and is likely to grow. It's important to keep in mind, though, that both Lilly and rivals may face some headwinds in the years to come, and that's why Goldman Sachs Research recently reduced its forecast for global sales of anti-obesity medicines to $95 billion by 2030, from an earlier forecast of $130 billion. This is due to several potential challenges, including lower per-unit prices and weaker reimbursement from certain insurers. But even considering the challenges, "we see a significant growth opportunity for both existing players as well as new entrants into this market," said Goldman analyst Asad Haider. After all, from today's $28 billion market, the forecast figure represents a 239% increase. A look at Lilly's weight loss drug sales shows us this company has the momentum to benefit from this high-growth market. Last year, Mounjaro and Zepbound generated more than $11 billion and $4.9 billion in sales, respectively. And these two products are driving double-digit total sales growth at Lilly -- with a 32% gain in the full year and a 45% gain in the most recent quarter. Now, what may push Lilly past Novo Nordisk -- and keep it far ahead of newer rivals down the road -- is the company's progress on an oral weight loss candidate. Current products are in injectable form, which may be less convenient and even uncomfortable for certain users. Lilly recently reported positive results from a phase 3 trial of its oral candidate, orforglipron, and plans to request approval for use in weight management by the end of the year. Though Novo Nordisk sells an oral form of semaglutide, it involves strict food and water guidelines. The potential Lilly product doesn't, offering it a significant advantage. Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward earnings estimates -- that's around the same level as top tech companies such as Amazon and Nvidia, also known for delivering double-digit revenue growth. In fact, since the launch of tirzepatide, Lilly has traded at valuations resembling those of growth stocks. So it may seem pricey to you for a pharmaceutical player. But it's worth keeping in mind that Lilly stands out from the pharma crowd due to its presence in the high-growth market of weight loss drugs, yet at the same time it offers you the stability and dividend growth of a pharma stock. You generally can count on big pharma companies for steady revenue since patients always need their medicines -- regardless of the economic situation. And you can count on Lilly for passive income too, with a forward dividend of $6, representing a dividend yield of 0.8%. Meanwhile, valuation has come down from its peak to levels that look very acceptable for a growth stock. All of this means that, by investing in Lilly, you're getting growth worthy of a tech company along with the safety generally associated with a pharma stock. That makes the stock well worth the price, and a great place to park $1,000 right now. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Goldman Sachs Group, and Nvidia. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Should You Invest $1,000 in Eli Lilly today? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may cause vision loss. Novo Nordisk A/S's (NYSE:NVO) semaglutide, a GLP-1 receptor agonist, is the active substance in certain medicines used for diabetes and obesity (Ozempic, Rybelsus, and Wegovy). After reviewing all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials, post-marketing surveillance and the medical literature, the committee on Friday concluded that NAION is a very rare side effect of semaglutide (meaning it may affect up to 1 in 10,000 people taking semaglutide).Results from several large epidemiological studies suggest that exposure to semaglutide in adults with type 2 diabetes is associated with an approximately two-fold increase in the risk of developing NAION compared with people not taking the medicine. This corresponds to approximately one additional case of NAION per 10,000 person-years of treatment; one person-year corresponds to one person taking semaglutide for one year. Data from clinical trials also point to a slightly higher risk of developing the condition in people taking semaglutide compared with people taking a placebo (a dummy treatment). Therefore, EMA has recommended that the product information for semaglutide medicines be updated to include NAION as a side effect with a frequency of 'very rare.' In December, a study conducted in Denmark and Norway revealed a potential link between the use of semaglutide for type 2 diabetes and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). Additionally, New research suggests that GLP-1 receptor agonists, widely prescribed for diabetes and weight loss, may significantly raise the risk of age-related macular degeneration in older diabetic patients. A study published on Thursday in JAMA Ophthalmology by the University of Toronto researchers warns of a potential downside: increased risk of neovascular age-related macular degeneration (nAMD) in diabetic users. nAMD is a severe form of age-related macular degeneration characterized by the growth of abnormal blood vessels in the back of the eye. Analyzing medical data from over 1 million Ontario residents with diabetes, researchers identified 46,334 patients prescribed GLP-1 RAs, most of whom were taking semaglutide—likely Ozempic, since Wegovy was only recently approved in Canada. Patients on these medications were matched with participants not on GLP-1 RAs, sharing similar demographics and health profiles, and tracked for three years. The study found that diabetic patients taking GLP-1 RAs for at least six months had double the risk of developing neovascular AMD compared to non-users. Over a mean follow-up period of 2.4 years, 0.2% of the GLP-1 RA cohort progressed to nAMD compared with only 0.1% of control participants, resulting in an increased hazard for nAMD of 2.21 for the GLP-1 RA cohort. The risk was also highest in those with the longest duration of exposure. The Guardian report added that those on the medications for more than 30 months had over three times the risk. The risk was even greater in older patients and those with a prior stroke. Recent findings from the 2025 American Clinical Society of Oncology annual conference suggested that patients using weight loss drugs, including Ozempic, were about 33% more likely to be diagnosed with kidney cancer compared to matched individuals not using the medication. Price Action: NVO stock is up 2.45% at $74.43 at the last check Friday. Read Next:Photo by Tobias Arhelger via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? NOVO NORDISK (NVO): Free Stock Analysis Report This article Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
